Media stories about Interpace Diagnostics Group (NASDAQ:IDXG) have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the business services provider an impact score of 45.782337250083 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Interpace Diagnostics Group (IDXG) opened at 1.30 on Friday. The stock has a 50 day moving average price of $0.99 and a 200-day moving average price of $1.88. The company’s market capitalization is $28.81 million. Interpace Diagnostics Group has a one year low of $0.07 and a one year high of $14.25.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. The business had revenue of $3.86 million during the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.

Separately, Maxim Group started coverage on Interpace Diagnostics Group in a report on Tuesday, August 15th. They issued a “buy” rating and a $5.00 price target on the stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Stock Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related stocks with our FREE daily email newsletter.